Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sartorius AG (GB:0NIR)
LSE:0NIR
Holding GB:0NIR?
Track your performance easily
0NIR Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€200.30 - €383.50
Previous Close€215
Volume26.93K
Average Volume (3M)23.90K
Market Cap
€13.54B
Enterprise Value€16.56B
Total Cash (Recent Filing)€196.80M
Total Debt (Recent Filing)€2.54B
Price to Earnings (P/E)177.5
Beta1.78
Next Earnings
Jan 23, 2025EPS Estimate
€1.07Last Dividend Ex-Date
Apr 02, 2024Dividend Yield0.34%
Share Statistics
EPS (TTM)1.21
Shares OutstandingN/A
10 Day Avg. Volume21,697
30 Day Avg. Volume23,903
Standard Deviation0.12
R-Squared0.03
Alpha0.00817
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)3.39
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€247.50Price Target Upside15.12% Upside
Rating ConsensusHold
Number of Analyst Covering13
Sartorius News
PremiumPre-Earnings
Is 0NIR a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Financial PerformanceA solid finish to the year is expected with likely positive risk/reward given trends into 4Q, cost cuts, and the more conservative guide towards the midpoint at the 3Q.
Order Intake GrowthSequential order intake growth of ~8% is a key positive.
Orderbook OutlookOrderbooks are improving, indicating a better outlook for Sartorius AG.
Bears Say
Financial PerformanceEBITDA decreased disproportionately from lower economies of scale.
Market ConditionsLPS continues to show weak end markets with reluctance for investment from customers, particularly in China.
Revenue ChallengesBioprocessing recovery is still slow, indicating challenges in achieving revenue targets.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
14.72% Mutual Funds
<0.01% Other Institutional Investors
78.22% Public Companies and
Individual Investors
0NIR FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest share price was €200.30 and its highest was €383.50 in the past 12 months.
What is Sartorius AG’s market cap?
Currently, no data Available
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Jan 23, 2025 which is in 31 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Oct 17, 2024. The company reported €0.21 earnings per share for the quarter, missing the consensus estimate of €0.859 by -€0.649.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Undervalued.
Does Sartorius AG pay dividends?
Sartorius AG pays a Annually dividend of €0.74 which represents an annual dividend yield of 0.34%. See more information on Sartorius AG dividends here
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is €1.07.
How many shares outstanding does Sartorius AG have?
Sartorius AG has 37,440,000 shares outstanding.
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of €0.21 in its last earnings report, missing expectations of €0.859. Following the earnings report the stock price went up 14.752%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in GB:0NIR
---
Sartorius Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.79%
12-Months-Change
Fundamentals
Return on Equity
3.51%
Trailing 12-Months
Asset Growth
-1.67%
Trailing 12-Months
Company Description
Sartorius AG
Sartorius AG is the leading provider of biopharmaceutical fermentation and fluid management. In 2019, the bioprocess division contributed 77% to total revenue and the lab division the remaining 23%. The bioprocess division is traded as a separate company, Sartorius Stedim Biotech. Sartorius AG has a 74% ownership of this subsidiary with 85% voting control. In addition to biomanufacturing equipment and consumables, Sartorius offers a wide range of products for general lab use, such as scales, pipettes, and filtration equipment. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (38% of 2019 sales), the Americas (37%), and Asia-Pacific (25%). Sartorius employs over 9,000 people and has operations in more than 30 countries.
---
0NIR Stock 12 Month Forecast
Average Price Target
€247.50
▲(15.12% Upside)
Technical Analysis
Best Analysts Covering 0NIR
1 Year
1 Year Success Rate
13/37 ratings generated profit
1 Year Average Return
+2.38%
reiterated a buy rating 20 days ago
Copying Richard Vosser's trades and holding each position for 1 Year would result in 35.14% of your transactions generating a profit, with an average return of +2.38% per trade.
---